The estimated Net Worth of Michelle L Basil is at least $16.4 Million dollars as of 28 May 2024. Ms. Basil owns over 12,990 units of Haemonetics stock worth over $2,264,570 and over the last 8 years she sold HAE stock worth over $11,598,563. In addition, she makes $2,542,440 as Executive Vice President and General Counsel at Haemonetics.
Sign up
Ms. Basil HAE stock SEC Form 4 insiders trading
Michelle has made over 26 trades of the Haemonetics stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 12,990 units of HAE stock worth $1,144,159 on 28 May 2024.
The largest trade she's ever made was selling 33,798 units of Haemonetics stock on 15 September 2022 worth over $2,632,526. On average, Michelle trades about 3,538 units every 63 days since 2017. As of 28 May 2024 she still owns at least 31,257 units of Haemonetics stock.
You can see the complete history of Ms. Basil stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michelle Basil biography
Michelle L. Basil J.D. serves as Executive Vice President, General Counsel of the Company. Ms. Basil was previously a Partner and Chair of the Life Sciences Practice Group at Nutter, McClennen & Fish LLP, a Boston-based law firm, where she practiced from September 1997 to March 2017. Ms. Basil focused her practice on corporate and securities law, including mergers and acquisitions, strategic partnerships and corporate governance matters, and represented both public and private companies, principally in the life sciences and medical technology industries. Ms. Basil is a member of the Board of Directors of the Massachusetts Medical Device Industry Council (MassMEDIC). She is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.
What is the salary of Michelle Basil?
As the Executive Vice President and General Counsel of Haemonetics, the total compensation of Michelle Basil at Haemonetics is $2,542,440. There are 2 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of $9,398,200.
How old is Michelle Basil?
Michelle Basil is 48, she's been the Executive Vice President and General Counsel of Haemonetics since 2017. There are 12 older and 1 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Insiders trading at Haemonetics
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
What does Haemonetics do?
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
What does Haemonetics's logo look like?
Complete history of Ms. Basil stock trades at Haemonetics
Haemonetics executives and stock owners
Haemonetics executives and other stock owners filed with the SEC include:
-
Christopher Simon,
President, Chief Executive Officer, Director -
William Burke,
Chief Financial Officer, Executive Vice President -
Michelle Basil,
Executive Vice President, General Counsel -
Josep Llorens,
Senior Vice President - Global Manufacturing and Supply Chain -
Jacqueline Scanlan,
Senior Vice President - Human Resources -
Richard Meelia,
Independent Chairman of the Board -
Claire Pomeroy,
Independent Director -
Charles Dockendorff,
Independent Director -
Catherine Burzik,
Independent Director -
Robert Abernathy,
Independent Director -
Ellen Zane,
Independent Director -
Mark Kroll,
Independent Director -
Olga Guyette,
Director – Investor Relations -
Michael Coyle,
Independent Director -
Anila Lingamneni,
Executive Vice President, Chief Technology Officer -
Dan Goldstein,
VP, Corporate Controller -
Susan Bartlett Foote,
Director -
Ronald G Gelbman,
Director -
Neil 122 62 507 Ryding,
EVP, Global Manufacturing -
David Fusco,
EVP, Global Human Resources -
Brian R Burns,
EVP, Global QA/RA -
Sandra Jesse,
VP & CLO -
Ronald Merriman,
Director -
Susan M Hanlon,
V.P. Corporate Controller -
Kent J Davies,
President, Global Markets -
Jonathan White,
VP Research and Development -
Byron Selman,
President, Global Markets -
Pedro P Granadillo,
Director -
Said Bolorforosh,
EVP, Chief Technology Officer -
William Granville,
VP, Manufacturing -
Thomas Lawlor,
President, Patient Division -
Brad Nutter,
President & CEO -
Yutaka Sakurada,
President, Japan & Asia -
Alicia R Lopez,
Senior VP & General Counsel -
Lawrence C Best,
Director -
Donna C E Williamson,
Director -
Warren Jr Nighan,
VP WW Q&R Affairs -
Ulrich Eckert,
President, Europe & Latin Am -
Mikael Gordon,
President, Haemonetics Europe -
Mark Beucler,
-
Anthony Pare,
-
Dave Helsel,
VP, Global Manufacturing -
Harvey G Klein,
Director -
Ryoji Sakai,
President, Japan -
Ronald A Matricaria,
Director -
Remi Corlin,
President, Asia -
Mark A Popovsky,
Vp, Corporate Medical Director -
Ronald J Ryan,
Senior VP & CFO -
Stephen Swenson,
VP & General Mgr, Global Plasm -
Peter M Allen,
President, Donor Division -
Brian Concannon,
President, Patient Division -
Kathleen Mc Daniel,
EVP Global Human Resources -
James O'shaughnessy,
-
Paul Black,
Director -
Michael I Ruxin,
VP Global Software Strategies -
Robert B Ebbeling,
Senior VP, Manufacturing -
Joseph J Forish,
VP, Human Resources -
Phillip John Brancazio,
VP, Global Manufacturing -
Michael P Kelly,
President, NA, Global Plasma -
William Roche Still,
VP Strategic Mktg, & Bus. Dev. -
Benjamin L Holmes,
Director -
Keiko Hattori,
President, Haemonetics Japan -
Jan Conneely,
VP & GM, Arryx, Inc. -
Christopher J Lindop,
VP, Finance & CFO -
Laurie A. Miller,
SVP, Human Resources -
Farris Maryanne Maunsell,
VP, Chief Accounting Officer -
Lloyd Emerson Johnson,
Director -
Stewart W Strong,
President, Global Hospital -
James D Arecca,
EVP, Chief Financial Officer -
Roy Galvin,
President, Global Plasma & BC -
Diane M Bryant,
Director